NCT02406885View on ClinicalTrials.gov

Apixaban Pharmacokinetics in Bariatric Patients (APB)

PHASE4CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

July 19, 2017

Primary Completion Date

February 1, 2020

Study Completion Date

February 1, 2020

Conditions
Bariatric SurgeryObesity
Interventions
DRUG

Apixaban

New Oral Anticoagulants (NOACs) are currently available for prophylaxis against venous thromboembolism in patients undergoing total hip or knee replacement surgery.

Trial Locations (1)

21224

The Johns Hopkins Center for Bariatric Surgery, Baltimore

All Listed Sponsors
lead

Johns Hopkins University

OTHER

NCT02406885 - Apixaban Pharmacokinetics in Bariatric Patients (APB) | Biotech Hunter | Biotech Hunter